ALUMIS INC. news, videos and press releases
For more news please use our advanced search feature.
ALUMIS INC. - More news...
ALUMIS INC. - More news...
- Alumis to Present at Leerink's 2025 Global Healthcare Conference
- Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
- Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
- Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
- Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
- Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
- Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
- Alumis Strengthens Leadership Team with Key Appointments
- Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
- Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
- Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
- Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
- Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
- Alumis to Participate in Upcoming September Investor Conferences
- Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
- Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
